Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS

Hospitals worldwide are experiencing a shortage in essential intravenous sedative medications. This is attributable to high number and high sedative needs of COVID-19 critical care patients with disruption of drug supply chains. Inhaled volatile anesthetic agents are an abundant resource and readily...

Descripción completa

Detalles Bibliográficos
Autores principales: Jerath, Angela, Ferguson, Niall D., Cuthbertson, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Narrative Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315695/
https://www.ncbi.nlm.nih.gov/pubmed/32588067
http://dx.doi.org/10.1007/s00134-020-06154-8
Descripción
Sumario:Hospitals worldwide are experiencing a shortage in essential intravenous sedative medications. This is attributable to high number and high sedative needs of COVID-19 critical care patients with disruption of drug supply chains. Inhaled volatile anesthetic agents are an abundant resource and readily implementable solution for providing ICU sedation. Inhaled volatile agents may also provide important pulmonary benefits for COVID-19 patients with ARDS that could improve gas exchange and reduce time spent on a ventilator. We review the use of volatile agents, and provide a technical overview and algorithm for administering inhaled volatile-based sedation in ICUs.

Ejemplares similares